Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370287 · ClinicalTrials.gov registry record · NA
Adaptive Optics Retinal Imaging
A NA study of Glaucoma, Primary Open Angle, sponsored by Food and Drug Administration (FDA).
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05370287: Recruiting NA study of Glaucoma, Primary Open Angle, sponsored by Food and Drug Administration (FDA).
NCT05370287 is a NA study of Glaucoma, Primary Open Angle that is actively recruiting participants, run by Food and Drug Administration (FDA). The registered enrollment target is 80 participants, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370287, a NA study of Glaucoma, Primary Open Angle, is actively recruiting participants, sponsored by Food and Drug Administration (FDA).
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
Primary Outcome
RBF \[uL/min\] will be measured from ensemble RBC velocity \[mm/s\] measurements from line-scan AOSLO videos and vessel diameter \[mm\] measurements from average AO-OCT volumes.
Conditions Studied
Interventions
- OTHER oxygen inhalation
- DEVICE Adaptive optics imaging
Study Locations (1)
Maryland
- Food and Drug Administration - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT05370287 shows while recruiting
NCT05370287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 2 interventions - of which oxygen inhalation is the first listed.
NCT05370287 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05370287 about?
NCT05370287 is a clinical study titled "Adaptive Optics Retinal Imaging". The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
What is the current status of trial NCT05370287?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2018-01-22. Estimated completion is 2026-09-30.
What conditions does trial NCT05370287 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT05370287?
The interventions under investigation include: oxygen inhalation (OTHER), Adaptive optics imaging (DEVICE).
Who is sponsoring clinical trial NCT05370287?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370287 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
RECRUITING · NA
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
-
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI